eBioscience™ Human Erythropoietin (EPO), Recombinant Protein

Human Recombinant Protein

Brand: eBioscience™

Manufacturer Part Number: 14-8992-62

5UG Human Erythropoietin (EPO) Recombinant Protein

Code: NEW

Additional Details:
Additional Details: Weight: 0.09500kg

Product Code. 15567556

Quantity Price
1 £92.20 / 5µg
Estimated Shipment date
from Supplier 02-11-2016
Add to basket

Description and Specification


Accession Number P01588
Concentration 0.1mg/mL
Conjugate Unlabeled
Cross Reactivity Human
For Use With (Application) Cytokine Bioassays
Formulation Sterile liquid; phosphate buffered saline with 1% BSA, pH 7.2 0.22μm filtered.
Molecular Weight The predicted molecular mass of this protein is 20.6kDa. It migrates at 34kDa by SDS-PAGE due to glycosylation.
Name Erythropoietin (EPO)
Purification Method SDS-PAGE
Purity >96%
Quantity 5μg
Recombinant Yes
Source CHO Cells
Storage Requirements For greatest stability, keep concentration of primary stock at or above 10μg/mL. For long term storage, aliquot into polypropylene vials (volumes of 20μL or greater) and store at less than or equal to -70°C. Avoid repeated freeze/thaw cycles.
Regulatory Status RUO
Structural Form CHO expressed amino acids Ala28-Arg193 accession number P01588
Endotoxin Concentration Less than 0.1ng/μg cytokine as determined by the LAL assay.
Biological Activity The ED50 of this protein, as measured by TF-1 cell proliferation assay, is 0.8-1ng/mL. This corresponds to a specific activity of 1-1.25x 106 Units/mg.
Product Type Recombinant Protein

Erythropoietin (EPO) protein is a growth factor essential for the survival, proliferation, and differentiation of erythroid precursors. EPO is not responsible for early commitment to the lineage, and instead induces the final maturation of partially differentiated erythroid cells and the production of red cell-specific proteins, such as hemoglobin. The EPO receptor (EPOR) is present in higher levels on precursor cells, and expression diminishes with cell maturation.

Hepatocytes are the main source of EPO in the fetus, followed by interstitial cells of the kidney after birth and through adulthood. EPO expression is upregulated during hypoxia, and low levels of transcription have also been detected in lung and brain tissue under these conditions. Recent data suggest that EPO may also play a role in the protection of neuronal tissue from damage and initiation of repair.